Last reviewed · How we verify
TAF with a boosted protease inhibitor
TAF with a boosted protease inhibitor is a Antiretroviral combination (nucleotide reverse transcriptase inhibitor + protease inhibitor) Small molecule drug developed by University of Colorado, Denver. It is currently FDA-approved for HIV-1 infection in treatment-experienced or treatment-naive adults. Also known as: Descovy with a boosted protease inhibitor.
TAF (tenofovir alafenamide) is a nucleotide reverse transcriptase inhibitor that, when combined with a boosted protease inhibitor, blocks HIV replication by inhibiting both reverse transcriptase and protease enzymes.
TAF (tenofovir alafenamide) is a nucleotide reverse transcriptase inhibitor that, when combined with a boosted protease inhibitor, blocks HIV replication by inhibiting both reverse transcriptase and protease enzymes. Used for HIV-1 infection in treatment-experienced or treatment-naive adults.
At a glance
| Generic name | TAF with a boosted protease inhibitor |
|---|---|
| Also known as | Descovy with a boosted protease inhibitor |
| Sponsor | University of Colorado, Denver |
| Drug class | Antiretroviral combination (nucleotide reverse transcriptase inhibitor + protease inhibitor) |
| Target | HIV reverse transcriptase and HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
TAF is a prodrug that delivers tenofovir to HIV-infected cells with improved intracellular activation and reduced systemic exposure compared to TDF. The boosted protease inhibitor (typically ritonavir-boosted) inhibits HIV protease, preventing the maturation of viral particles. Together, these agents provide dual suppression of HIV replication through complementary mechanisms.
Approved indications
- HIV-1 infection in treatment-experienced or treatment-naive adults
Common side effects
- Diarrhea
- Nausea
- Headache
- Lipid elevation
- Gastrointestinal disturbance
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- The Late Presenter Treatment Optimisation Study (PHASE3)
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen (PHASE2, PHASE3)
- Effect on HIV Medications on EPC Cells
- Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants (PHASE3)
- Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) (PHASE4)
- Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAF with a boosted protease inhibitor CI brief — competitive landscape report
- TAF with a boosted protease inhibitor updates RSS · CI watch RSS
- University of Colorado, Denver portfolio CI
Frequently asked questions about TAF with a boosted protease inhibitor
What is TAF with a boosted protease inhibitor?
How does TAF with a boosted protease inhibitor work?
What is TAF with a boosted protease inhibitor used for?
Who makes TAF with a boosted protease inhibitor?
Is TAF with a boosted protease inhibitor also known as anything else?
What drug class is TAF with a boosted protease inhibitor in?
What development phase is TAF with a boosted protease inhibitor in?
What are the side effects of TAF with a boosted protease inhibitor?
What does TAF with a boosted protease inhibitor target?
Related
- Drug class: All Antiretroviral combination (nucleotide reverse transcriptase inhibitor + protease inhibitor) drugs
- Target: All drugs targeting HIV reverse transcriptase and HIV protease
- Manufacturer: University of Colorado, Denver — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-experienced or treatment-naive adults
- Also known as: Descovy with a boosted protease inhibitor
- Compare: TAF with a boosted protease inhibitor vs similar drugs
- Pricing: TAF with a boosted protease inhibitor cost, discount & access